Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]HRS-1780 in Healthy Male Subjects
NCT07557407Phase 1Not yet recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- May 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-1780 in chronic kidney disease (CKD), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Total radioactivity ratio of whole blood/plasma, Time to Maximum Plasma Concentration and 9 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
HRS-1780
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07557407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07557407.